Citius raises $36.5m for Lymphir commercialisation

Citius Oncology has secured up to $36.5m successful a operation of indebtedness and equity financing to accelerate the commercialisation of Lymphir (denileukin diftitox-cxdl), a recombinant fusion macromolecule immune therapy.

The therapy is approved by the US Food and Drug Administration (FDA) for big patients with relapsed oregon refractory Stage I-III cutaneous T-cell lymphoma (CTCL) pursuing astatine slightest 1 anterior systemic treatment.

The superior includes a elder secured word indebtedness installation of up to $25m from Avenue Venture Opportunities Fund II, arsenic good arsenic a warrant workout statement expected to output $11.5m.

HC Wainwright & Co is serving arsenic the exclusive origination, structuring, and placement cause for these financings.

The word indebtedness spans 3 and a fractional years, consisting of an archetypal $10m tranche astatine closing and 2 further tranches totalling up to $15m, contingent connected gross and liquidity milestones.

Avenue volition person warrants to bargain up to 11.1 cardinal shares astatine an workout terms of $0.90 per share, with a five-year exercisability window, alongside conversion rights for up to $4m.

Citius Oncology’s definitive agreements with a healthcare-focused organization capitalist impact contiguous workout of warrants for up to 12.7 cardinal shares, generating astir $11.5m, offset by the contented of caller unregistered warrants.

Proceeds volition money Lymphir's commercialisation, marketplace access, aesculapian affairs, and manufacturing, arsenic good arsenic supply moving capital.

Denileukin diftitox holds approvals successful Japan and the US and is licensed globally but successful India, Japan, and parts of Asia.

Citius Oncology and Citius Pharmaceuticals president and CEO Leonard Mazur said: “This recognition installation strengthens our quality to proceed to execute connected the Lymphir launch, aligning superior entree with commercialized performance, and underscoring the assurance that a planetary concern steadfast similar Avenue Capital has successful our commercialized trajectory and the semipermanent imaginable of Lymphir.

“In parallel, the warrant workout financing provides further near-term superior to further enactment our commercialized efforts. Collectively, this provides the institution with meaningful fiscal flexibility arsenic we proceed to standard our commercialized infrastructure, thrust adoption of Lymphir among treating physicians, and grow diligent entree to this important therapy for relapsed oregon refractory cutaneous T-cell lymphoma.”

Earlier this year, Citius Oncology signed an exclusive organisation statement with Uniphar to alteration entree to Lymphir successful selected European countries.

"Citius raises $36.5m for Lymphir commercialisation" was primitively created and published by Pharmaceutical Technology, a GlobalData owned brand.